Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06446947
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-06
First Post:
2024-05-29
Brief Title:
Identification of Markers of Poor Clinical Prognosis in Sepsis by Epigenetic Analysis
Sponsor:
Assistance Publique Hopitaux De Marseille
Organization:
Assistance Publique Hopitaux De Marseille
Study Overview
Official Title:
Identification de Marqueurs de Mauvais Pronostic Clinique du Sepsis Par Analyse épigénétique
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EPISEPSIS
Brief Summary:
Sepsis is a multifactorial syndrome characterized by a dynamic course and a clinical outcome dependent on several factors and responsible for one in five deaths worldwide The aim of this trial is to identify new prognostic markers for the progression of sepsis to septic shock by comparing epigenetic markers between patients who have or have not developed severe forms of sepsis
The main objective of this preliminary study is to identify prognostic markers for the progression of sepsis to septic shock ie to compare targeted markers between subjects with sepsis who progress to septic shock versus subjects with sepsis who do not progress to septic shock
The main objective of this preliminary study is to identify prognostic markers for the progression of sepsis to septic shock ie to compare targeted markers between subjects with sepsis who progress to septic shock versus subjects with sepsis who do not progress to septic shock
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None